NCT06659562 - Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

August 14, 2025

Study Completion Date

August 20, 2025

Conditions

Parkinson Disease, Idiopathic

Interventions

DRUG

HER-096

Administered as a single dose via s.c. injection

DRUG

HER-096

Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.

DRUG

Placebo

Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.

Trial Locations (1)

Clinical Research Services Turku - CRST Oy, Turku